Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis

Yao, Weiqi; Dong, Haibo; Qi, Ji; Shi, Lei

doi:10.1016/j.eclinm.2022.101545

Cited by 20 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall survival decreased to 82% at the 3-month follow-up. These results were further corroborated by two meta-analyses assessing the efficacy and safety of MSCs in treating severe/ critical COVID-19 which concluded that MSCs reduced in-hospital mortality with low heterogeneity and less adverse events, improved patients' oxygenation status, contributed to a reduction in viral load, inflammation, and mortality with improvement on radiological imaging [126,127]. Despite the promising results, patients with active malignancy (except for those with non-melanoma skin cancer) were excluded from this study.…”

Section: Mesenchymal Stem Cell Therapymentioning

confidence: 77%

Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients

et al. 2023

View full text Add to dashboard Cite

Cancer patients, due to their immunocompromised status, are at an increased risk for severe SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage through IL-6-mediated inflammation while stimulating hypoxia, and malignancy promotes hypoxia-induced cellular metabolic alterations leading to cell death, we propose a mechanistic interplay between both conditions that results in an upregulation of IL-6 secretion resulting in enhanced cytokine production and systemic injury. Hypoxia mediated by both conditions results in cell necrosis, dysregulation of oxidative phosphorylation, and mitochondrial dysfunction. This produces free radicals and cytokines that result in systemic inflammatory injury. Hypoxia also catalyzes the breakdown of COX-1 and 2 resulting in bronchoconstriction and pulmonary edema, which further exacerbates tissue hypoxia. Given this disease model, therapeutic options are currently being studied against severe SARS-COV-2. In this study, we review several promising therapies against severe disease supported by clinical trial evidence—including Allocetra, monoclonal antibodies (Tixagevimab–Cilgavimab), peginterferon lambda, Baricitinib, Remdesivir, Sarilumab, Tocilizumab, Anakinra, Bevacizumab, exosomes, and mesenchymal stem cells. Due to the virus’s rapid adaptive evolution and diverse symptomatic manifestation, the use of combination therapies offers a promising approach to decrease systemic injury. By investing in such targeted interventions, cases of severe SARS-CoV-2 should decrease along with its associated long-term sequelae and thereby allow cancer patients to resume their treatments.

show abstract

Section: Mesenchymal Stem Cell Therapymentioning

confidence: 77%

Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Additional emerging therapies being investigated are interferon therapy [ 18 •, 87 ], granulocyte-macrophage colony-stimulating factor inhibitors [ 88 , 89 ], and mesenchymal stem cell therapy [ 90 , 91 ]; however, currently, no high-quality evidence exists to support their use outside of clinical trials.…”

Section: Non-recommended Therapiesmentioning

confidence: 99%

Current and Emerging Therapies for COVID-19 in Lung Transplantation

et al. 2023

View full text Add to dashboard Cite

Purpose of Review The landscape of the coronavirus disease 2019 (COVID-19) pandemic has rapidly changed over the past 3 years. Paralleling this evolution, the scientific and medical communities have reported many novel findings relating to the infection’s epidemiology, transmission, diagnosis, and treatment. We review pertinent studies of COVID-19 therapeutics with an emphasis on their application to lung transplant recipients. Recent Findings Agents that have been well-studied for treating COVID-19 include antivirals (remdesivir, nirmatrelvir/ritonavir, molnupiravir), monoclonal antibodies, and immunomodulators (for example, corticosteroids and tocilizumab). Summary Remdesivir remains an essential therapy for managing mild-moderate COVID-19. Though highly efficacious for mild-moderate COVID-19 for outpatient therapy, ritonavir-boosted nirmatrelvir has limited use in lung transplant recipients due to significant drug-drug interactions. Monoclonal antibodies, though useful, are the most affected by the emergence of new viral variants.

show abstract

“…It has been reported in the literature that effective inflammatory factors of cytokine storms (for example IL-1a, TNF -α, etc.) may be reduced and the anti-inflammatory factors would be up-regulated in case of utilizing MSCs (Wang et al 2014 ; Yao et al 2022 ). In addition, the function of crucial immune sensors known as toll-like receptors for identifying invasive pathogens such as viruses could be regulated by MSCs in order to debarment of cytokine storms (Pevsner-Fischer et al 2007 ; Tomchuck et al 2008 ).…”

Section: Mscs Therapymentioning

confidence: 99%

The promising approach of MSCs therapy for COVID-19 treatment

et al. 2022

View full text Add to dashboard Cite

Several ongoing investigations have been founded on the development of an optimized therapeutic strategy for the COVID-19 virus as an undeniable acute challenge for human life. Cell-based therapy and particularly, mesenchymal stem cells (MSCs) therapy has obtained desired outcomes in decreasing the mortality rate of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), mainly owing to its immunoregulatory impact that prevents the overactivation of the immune system. Also, these cells with their multipotent nature, are capable of repairing the damaged tissue of the lung which leads to reducing the probability of acute respiratory distress syndrome (ARDS). Although this cell-based method is not quite cost-effective for developing countries, regarding its promising results in order to treat SARS-COV-2, more economical evaluation as well as clinical trials should be performed for improving this therapeutic approach. Here in this article, the functional mechanism of MSCs therapy for the treatment of COVID-19 and the clinical trials based on this method will be reviewed. Moreover, its economic efficiency will be discussed.

show abstract

Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis

Cited by 20 publications

References 48 publications

Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients

Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients

Current and Emerging Therapies for COVID-19 in Lung Transplantation

The promising approach of MSCs therapy for COVID-19 treatment

Contact Info

Product

Resources

About